3651 results for «315»
3651 results
Coronary artery access and revascularisation after TAVI
21 Nov 2021 – From PCR London Valves 2021
Find out more about coronary access post-TAVI in this PCR London Valves 2021 session, witness a coronary intervention after self-expanding TAVI or SAVR in low-risk patients, and review two-year outcomes following TAVI or SAVR in patients stratified by need for revascularisation, among others!
Pacemaker implantation after TAVI
21 Nov 2021 – From PCR London Valves 2021
Through this series of videos from PCR London Valves 2021, learn about the early outcomes of using the novel frame alignment technique during TAVI to improve pacemaker rates, see how cusp overlap projection reduces the burden of permanent pacemaker implantation after TAVR, appreciate the clinical utility of...
TAVI in bicuspid aortic valves
21 Nov 2021 – From PCR London Valves 2021
Thanks to this series of videos from PCR London Valves 2021, analyze the results of self-expandable versus balloon-expandable transcatheter valves in bicuspid aortic anatomy, study the outcomes after TAVI in bicuspid aortic valve, and much more!
TAVI procedure planning and optimising patient outcomes
21 Nov 2021 – From PCR London Valves 2021
Watch this series of videos from PCR London Valves 2021 to evaluate whether TAVICT scans can replace invasive coronary angiography pre-TAVI, to appreciate how pre-operative computed tomography evaluation of aortic burden can predict acute kidney injury post-TAVR, and to appraise mortality in TAVI patients converted to...
PCR London Valves 2021 Hotlines / Late-Breaking Trials: GALILEO, JenaValve TAVI, ENVISAGE TAVI AF, VKA in patients with AF after TAVI
21 Nov 2021 – From PCR London Valves 2021
In this session, find out more about the JenaValve TAVI system in patients with aortic regurgitation, get results from the GALILEO trial, review a late-breaking on-treatment major bleeding analysis from the ENVISAGE TAVI AF trial, and explore the safety and efficacy of edoxaban versus VKA in patients with AF...
Outcomes after novel transcatheter and surgical tricuspid valve interventions
21 Nov 2021 – From PCR London Valves 2021
Find out more about TRI-SCORE, a new risk score to predict in-hospital mortality after isolated tricuspid valve surgery, 30-day outcomes for transcatheter tricuspid repair from the TriBAND study, both the CLASP TR early feasibility and TRISCEND studies six-month results, and more in this PCR London Valves...
Transcatheter mitral, aortic and pulmonary valve implantation
21 Nov 2021 – From PCR London Valves 2021
Watch this series of videos from PCR London Valves 2021 to learn about acute heart failure hospitalizations following TAVI in the U.S., share a peripheral hospital's experiences with structural valve service modernization, enjoy percutaneous transseptal mitral valve implantation in Brazil, and more!
Outcomes following transcatheter and percutaneous mitral valve repair
21 Nov 2021 – From PCR London Valves 2021
CLASP study, predictability of post-delivery residual mitral regurgitation, MiCLASP PMCF study, off-pump transapical neochord implantation, pronostic impact of nutritional status, and patients with low, intermediate and high frailty are the focus of this session from PCR LV 2021 devoted to percutaneous and transcatheter mitral valve repair.
Preventive PCI or medical therapy alone for atherosclerotic coronary vulnerable plaques (PREVENT)
08 Apr 2024
Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes: The multicenter, randomized, blinded, IVUS-ACS Trial
09 Apr 2024
Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)
Author
Author
